Cyramza 500 mg Injection Cyramza contains Ramucirumab, a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor-2 (VEGFR-2). By blocking the interaction of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D) with VEGFR-2, it inhibits receptor activation and downstream signaling pathways involved in tumor angiogenesis, vascular permeability, and endothelial cell proliferation. It is indicated as monotherapy or in combination with chemotherapy for the treatment of advanced or metastatic gastric/gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and hepatocellular carcinoma (HCC).